OncoFAP is a small molecule radiotracer for the non-invasive detection of a variety of metastatic solid tumors targeting Fibroblast Activation Protein (FAP). FAP is overexpressed in more than 90% of the epithelial cancers, including malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas.

The OncoFAP product consists of a (i) small ligand targeting FAP, (ii) an innovative spacer structure and (iii) a DOTAGA chelator. OncoFAP-68Ga is being developed for the imaging of a panel of different tumor entities. If dosimetric results are adequate, the beta-emitting counterpart (OncoFAP-177Lu) could be used for therapeutic applications.

OncoFAP displays best-in-class performance with the highest reported affinity to the FAP antigen. In preclinical models of cancer, the product shows a very rapid and efficient accumulation in tumors (>30% of the injected dose per gram of tumor, ten minutes after the intravenous administration) and exceptionally low kidney uptake.


  • OncoFAP-68Ga has recently entered in a first-in-man imaging study in breast cancer patients.


By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy